(en) A. Marques (september 2022). Persistent Symptoms After Treatment of Lyme Disease. Infectious Disease Clinics of North America 36 (3): 621–638. PMID: 36116839. PMC: 9494579. DOI:10.1016/j.idc.2022.04.004.
(en) A. Marques (september 2022). Persistent Symptoms After Treatment of Lyme Disease. Infectious Disease Clinics of North America 36 (3): 621–638. PMID: 36116839. PMC: 9494579. DOI:10.1016/j.idc.2022.04.004.
Paul Mead et al. Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease, MMWR Morb Mortal Wkly Rep. 2019 Aug 16; 68(32): 703. Bron online: PMC6818702
"On July 29, 2019, FDA cleared several Lyme disease serologic assays with new indications for use based on a modified two-test methodology (4). The modified methodology uses a second EIA in place of a western immunoblot assay. Clearance by FDA of the new Lyme disease assays indicates that test performance has been evaluated and is “substantially equivalent to or better than” a legally marketed predicate test."
